AbCellera Biologics

The company integrates biology, computation, and engineering in a platform for developing differentiated antibody-based medicines.

AbCellera's co-founder and Head of Business Development Kevin Heyries, Ph.D., presents on combining immune repertoire sequencing with functionally validated single-cell data to expand antibody diversity for lead identification.

Bo Barnhart, VP, Translational Research at AbCellera, will be presenting a poster at the AACR Annual Meeting.

AbCellera will be presenting two posters at AACR 2023:

AbCellera will be presenting four posters at AACR 2024:

The company hires for character, intelligence, drive, energy, and trust rather than relying only on CVs or experience.

The company is an early-stage biotech developing medicines for conditions with high unmet medical need.

The company provides contact information, global office addresses, and a contact form.

The company advances antibody drug programs across multiple indications and modalities.

AbCellera describes its commitment to protecting personal information and explains how it collects, uses, and safeguards data.

AbCellera prices an oversubscribed underwritten public offering of common shares and pre-funded warrants, targeting approximately $200 million in gross proceeds. The offering includes 17,435,897 common shares priced at $9.75 each, alongside pre-funded warrants; net proceeds are intended to support continued research, development, and clinical advancement of its internal pipeline, including lead clinical program ABCL635.

Aug 2026 · StockTitanNews article

AbCellera reports positive top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational NK3 receptor antagonist antibody. After a single 600 mg subcutaneous dose, the treatment significantly reduces the frequency and severity of moderate-to-severe menopausal vasomotor symptoms versus placebo, meets primary efficacy endpoints, and shows a favorable tolerability profile.

Aug 2026 · StockTitanNews article

AbCellera reports second-quarter 2026 revenue of $4.1 million, a net loss of $55.4 million, and more than $565 million in cash and marketable securities at quarter-end. It also discloses its collaborations with Jazz Pharmaceuticals and Vertex and reports continued clinical progress in its ABCL635 and ABCL575 programs.

Aug 2026 · StockTitanNews article

AbCellera collaborates with Vertex Pharmaceuticals to research, develop, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. The agreement provides AbCellera with $28 million in upfront payments, eligibility for preclinical, development, regulatory, and commercial milestone payments, and tiered royalties on net sales.

Jul 2026 · StockTitanNews article